Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 3-Year Revenue Growth Rate is 17.10% as of Dec. 2025, which is 146% above its 10-year median of 6.95. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 757 Medical Devices & Instruments companies, NIOX Group ranks better than 80.45% on this metric.
During the past 12 months, NIOX Group's average Revenue per Share Growth Rate was 22.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 17.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of NIOX Group was 48.20% per year. The lowest was -24.30% per year. And the median was 6.95% per year.
NIOX Group (OTCPK:CSSPF) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
NIOX Group 3-Year Revenue Growth Rate Related Terms
CSSPF vs ABT, SYK, MDT: 3-Year Revenue Growth Rate Comparison
For the Medical Devices subindustry, NIOX Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group 3-Year Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where NIOX Group's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 17.10% mean?
NIOX Group (CSSPF) has a 3-Year Revenue Growth Rate of 17.10% as of Dec. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for NIOX Group and its competitors. This is 146% above median its historical median of 6.95. According to the industry distribution chart, NIOX Group ranks #148 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 19.6%.
Is NIOX Group's 3-Year Revenue Growth Rate too high?
NIOX Group's current 3-Year Revenue Growth Rate of 17.10% is 146% above median its 10-year median of 6.95. The Medical Devices & Instruments industry median 3-Year Revenue Growth Rate is 3.70. NIOX Group's value of 17.10% is 362.2% above this industry median. Based on the distribution chart, NIOX Group ranks #148 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 3-Year Revenue Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #148 out of 757 companies for 3-Year Revenue Growth Rate. This places NIOX Group in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 3.70. NIOX Group's value of 17.10% is 362.2% above this benchmark. While the company's 10-year median is 6.95 vs. the industry median of 3.70, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Revenue Growth Rate among Medical Devices & Instruments companies is 3.70, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current 3-Year Revenue Growth Rate of 17.10% is 362.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current 3-Year Revenue Growth Rate is 17.10%, which is 146% above median its own 10-year median of 6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.22, compared to a current price of $0.82 — trading 32.8% below its estimated fair value. The current 3-Year Revenue Growth Rate is 17.10%, which is 146% above median its 10-year median of 6.95 and 362.2% above the Medical Devices & Instruments industry median of 3.70. NIOX Group's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 3-Year Revenue Growth Rate is 17.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.8% below its estimated GF Value™ of $1.22.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
3-Year Revenue Growth Rate: 17.10% (146% above median its 10-year median of 6.95)
GF Value™: $1.22 vs. price of $0.82 (32.8% below fair value)
Industry Position: 362.2% above the Medical Devices & Instruments median (#148 of 757)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
